Amgen traded at $253.09 this Thursday May 26th, increasing $0.08 or 0.03 percent since the previous trading session. Looking back, over the last four weeks, Amgen gained 1.73 percent. Over the last 12 months, its price rose by 7.56 percent. Looking ahead, we forecast Amgen to be priced at 241.36 by the end of this quarter and at 223.91 in one year, according to Trading Economics global macro models projections and analysts expectations.

Stock Price
253.09
Daily Change
0.03%
Yearly
7.56%

Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Peers Price Day Year
Takeda 3,761.00 -1.00 -0.03% -1.29%
AbbVie 150.57 -1.40 -0.92% 34.05%
Agios Pharmaceuticals 19.97 0.34 1.73% -64.54%
ALKERMES 28.89 0.04 0.14% 29.49%
Amgen 253.09 0.08 0.03% 7.56%
Astrazeneca 66.85 0.04 0.06% 18.23%
Biogen 204.27 1.91 0.94% -23.60%
Bluebird Bio 3.25 0.25 8.33% -89.53%
BioMarin Pharmaceutical 79.53 0.60 0.76% 2.91%
Bristol-Myers Squibb 77.58 0.34 0.44% 18.06%
Coherus Biosciences 7.69 0.28 3.78% -41.61%
Exelixis 18.02 0.21 1.15% -19.58%
Genmab 2,138.00 14.00 0.66% -12.12%
Gilead Sciences 64.50 -0.52 -0.79% -2.13%
GlaxoSmithKline 1,776.20 1.20 0.07% 32.55%
Glaxosmithkline 44.89 -0.09 -0.19% 15.95%
Intercept Pharmaceuticals 17.16 0.34 2.02% 2.75%
Incyte Corp 76.03 -0.48 -0.63% -8.04%
Ionis Pharmaceuticals 37.34 0.48 1.30% 5.12%
J&J 179.54 -0.08 -0.04% 6.36%
Eli Lilly 313.33 6.32 2.06% 57.29%
Merck & Co 92.35 -1.40 -1.49% 21.64%
Moderna Inc 135.81 4.96 3.79% -24.36%
Mirati Therapeutics 58.53 0.51 0.88% -61.15%
Neurocrine Biosciences 89.76 1.38 1.56% -6.80%
Novartis 88.13 0.45 0.51% 10.93%
Novartis 91.43 0.18 0.20% 2.55%
Puma Biotechnology 1.94 0.03 1.57% -81.15%
Pfizer 54.03 0.32 0.59% 39.78%
PTC Therapeutics 30.83 0.25 0.82% -22.58%
Ultragenyx Pharmaceutical 46.15 0.23 0.50% -55.15%
Regeneron Pharmaceuticals 683.17 -7.71 -1.12% 37.92%
Roche Holding 332.60 1.15 0.35% 6.50%
Sanofi 103.72 0 0% 19.40%
Seattle Genetics 136.90 0.43 0.32% -9.27%
Sarepta Therapeutics 70.26 1.77 2.58% -6.26%
Teva Pharmaceutical Industries Ltd 2,979.00 69.00 2.37% -13.58%
Vertex Pharmaceuticals 269.70 -1.15 -0.42% 30.09%

Indexes Price Day Year
US500 4054 79.11 1.99% -3.57%
USND 11741 305.91 2.68% -14.53%
USNDX 12264 332.86 2.79% -10.39%
US30 32597 516.91 1.61% -5.60%

Amgen
Amgen Inc. is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes ENBREL, Prolia (denosumab), Neulasta (pegfilgrastim), Otezla, XGEVA, Aranesp (darbepoetin alfa), KYPROLIS, Repatha (evolocumab), Nplate (romiplostim), Vectibix (panitumumab), MVASI (bevacizumab-awwb), Parsabiv (etelcalcetide), EPOGEN (epoetin alfa), KANJINTI (trastuzumab-anns), BLINCYTO (blinatumomab), Aimovig (erenumab-aooe), EVENITY (romosozumab-aqqg), AMGEVITATM (adalimumab), Sensipar/Mimpara (cinacalcet), NEUPOGEN (filgrastim), IMLYGIC (talimogene laherparepvec), Corlanor (ivabradine) and AVSOLA (infliximab-axxq). It focuses on human therapeutics for the treatment of serious illness in the areas of inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology and neuroscience.